Columbia University

Technology Ventures

Latest News

Applications are now open for the fifth cycle of PowerBridgeNY! If you are a researcher, post-doctoral candidate, or PhD candidate with a promising technology that could have a positive environmental impact – we want to talk to you!

This article reviews some of the lessons learned by Columbia University in five years of managing or co-managing proof-of-concept center accelerators for grant-funded technologies in three industries: medical devices, diagnostics, and imaging; clean energy; and media.

A new study by the Milken Institute ranks Columbia University as number two in the country for commercializing science and technology emerging from university research labs.

TheraPten Biosciences Inc., a Canadian biotechnology company, has entered into an exclusive licensing agreement with Columbia University on two globally issued patent families covering PTEN-L, a naturally-occurring tumor suppressor protein.

Applied Therapeutics Inc., today announced the closing of its Series A financing round. The financing was led by Alexandria Venture Investments alongside E Squared Capital Management, Franklin Berger, ETP Global Fund and Syno Capital. Joel S.

Doctor Rebecca Brachman has been selected as a TED Fellow, joining a class of 15 change-makers from around the world who will deliver a talk on the TED stage this April in Vancouver.

Lin Bioscience and Columbia Technology Ventures announced that Lin Bioscience has licensed the intellectual property portfolio and development program for a promising first-in-class medication intended to slow or halt the progression of atrophic "Dry" Age-Related Macular Degeneration (AMD).  

Fortress Biotech, Inc. announced the formation of a new subsidiary company, Caelum Biosciences, Inc., to advance the development of CAEL‐ 101 (11‐1F4) for the treatment of amyloid light chain (“AL”) amyloidosis.